ATE326484T1 - Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie - Google Patents

Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie

Info

Publication number
ATE326484T1
ATE326484T1 AT95922533T AT95922533T ATE326484T1 AT E326484 T1 ATE326484 T1 AT E326484T1 AT 95922533 T AT95922533 T AT 95922533T AT 95922533 T AT95922533 T AT 95922533T AT E326484 T1 ATE326484 T1 AT E326484T1
Authority
AT
Austria
Prior art keywords
diagnosis
therapy
monoclonal antibody
tyrosine kinase
antibody against
Prior art date
Application number
AT95922533T
Other languages
English (en)
Inventor
Kari Alitalo
Of Helsinki Uni
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Marja-Terttu Matikainen
Katri Pajusola
Paeivi Karnani
Original Assignee
Licensing Oy
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licensing Oy, Orion Corp filed Critical Licensing Oy
Application granted granted Critical
Publication of ATE326484T1 publication Critical patent/ATE326484T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95922533T 1994-06-09 1995-06-09 Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie ATE326484T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25775494A 1994-06-09 1994-06-09

Publications (1)

Publication Number Publication Date
ATE326484T1 true ATE326484T1 (de) 2006-06-15

Family

ID=22977612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922533T ATE326484T1 (de) 1994-06-09 1995-06-09 Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie

Country Status (14)

Country Link
EP (1) EP0807124B1 (de)
JP (4) JP3723210B2 (de)
AT (1) ATE326484T1 (de)
AU (1) AU694524B2 (de)
CA (1) CA2192235C (de)
DE (1) DE69534996T2 (de)
DK (1) DK0807124T3 (de)
ES (1) ES2263152T3 (de)
FI (1) FI964862A (de)
MX (1) MX9606218A (de)
NO (1) NO319383B1 (de)
NZ (1) NZ288235A (de)
PT (1) PT807124E (de)
WO (1) WO1995033772A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
JP4841724B2 (ja) 1998-10-09 2011-12-21 ベジェニクス ピーティーワイ リミテッド 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2002540814A (ja) * 1999-04-13 2002-12-03 ノースウエスト バイオセラピューティクス，インコーポレイティド 転移性前立腺腫瘍の診断および処置のための方法
EP1553414A1 (de) * 1999-04-13 2005-07-13 Medarex, Inc. Methoden zur Diagnose und Behandlung metastasierender Prostata-Tumore
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6599717B1 (en) * 1999-10-01 2003-07-29 Exelixis, Inc. Invertebrate vascular endothelial growth factor receptor
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
WO2007138143A2 (es) * 2006-05-29 2007-12-06 Consejo Superior De Investigaciones Cientificas Anticuerpos monoclonales anti-colina quinasa alfa y su uso en técnicas analíticas, de diagnóstico del cáncer y en la preparación de medicamentos
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620826A1 (de) * 1992-01-09 1994-10-26 Helsinki University Holding, Ltd. Tie, eine neuartiger tyrosinkinase-rezeptor in endothelzellen
ES2360641T3 (es) * 1992-10-28 2011-06-07 Genentech, Inc. Uso de antagonistas del factor de crecimiento endotelial vascular.

Also Published As

Publication number Publication date
JP2009102415A (ja) 2009-05-14
AU2738895A (en) 1996-01-04
JPH10500858A (ja) 1998-01-27
JP2005139199A (ja) 2005-06-02
NZ288235A (en) 1999-05-28
JP2012193191A (ja) 2012-10-11
MX9606218A (es) 1998-02-28
CA2192235A1 (en) 1995-12-14
FI964862A (fi) 1997-02-10
DK0807124T3 (da) 2006-08-28
NO965231L (no) 1996-12-06
CA2192235C (en) 2011-02-15
NO965231D0 (no) 1996-12-06
NO319383B1 (no) 2005-07-25
WO1995033772A1 (en) 1995-12-14
FI964862A0 (fi) 1996-12-04
PT807124E (pt) 2006-08-31
AU694524B2 (en) 1998-07-23
EP0807124B1 (de) 2006-05-17
ES2263152T3 (es) 2006-12-01
JP3723210B2 (ja) 2005-12-07
DE69534996T2 (de) 2007-05-10
EP0807124A1 (de) 1997-11-19
DE69534996D1 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
ATE326484T1 (de) Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie
PT914345E (pt) Ligacao de anticorpos a receptores (ccr2) de proteina 1 de quimio-atraccao de monocitos (pqm-1)
DE69417417D1 (de) Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen
CA2250141A1 (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
ATE202849T1 (de) Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung
DK0540573T3 (da) Assay for frit- og kompleksbundet prostataspecifikt antigen (PSA)
NO974534D0 (no) Bestemmelse av cPSA
DE69637909D1 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
TR200103011T2 (tr) Bulaşıcı sünger tipi ansefalopatilerinin teşhisine yönelik metod.
DE3780480D1 (de) Test fuer menschlichen brustkrebs.
NO177463C (no) STLV-III-beslektede polypeptider, diagnostiske prövesett og in vitro analysefremgangsmåte for påvisning av anti-HIV-2-antistoffer i kroppsvæskepröve
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
DE69229948D1 (de) hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN
ATE433575T1 (de) Neurotransmission-störungen
DE69523492D1 (de) Immunoassay-Reagenzien, Testsätze und Verfahren
ES2168378T3 (es) Determinacion de tripsinogeno-2 libre y en forma de complejo.
ES2189254T3 (es) Dosificado inmunologico que permite detectar los anticuerpos igm especificos del citomegalovirus humano.
WO1990008956A1 (fr) Detection d'activateur de facteur tissulaire humain
NO20022276D0 (no) Human neurokinin-B-forlöper fra placenta
UA29191A (uk) Спосіб діагностики плацентарної недостатності

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0807124

Country of ref document: EP

REN Ceased due to non-payment of the annual fee